Cargando…
Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype
Even the most advanced drug-eluting stents evoke unresolved issues, including chronic inflammation, late thrombosis, and neoatherosclerosis. This highlights the need for novel strategies that improve stent biocompatibility. Our studies show that apolipoprotein A-I (apoA-I) reduces in-stent restenosi...
Autores principales: | Vanags, Laura Z., Tan, Joanne T.M., Galougahi, Keyvan K., Schaefer, Andreas, Wise, Steven G., Murphy, Andrew, Ali, Ziad A., Bursill, Christina A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060078/ https://www.ncbi.nlm.nih.gov/pubmed/30062205 http://dx.doi.org/10.1016/j.jacbts.2017.11.006 |
Ejemplares similares
-
Strikingly Different Atheroprotective Effects of Apolipoprotein A-I in Early- Versus Late-Stage Atherosclerosis
por: Morton, Jamie, et al.
Publicado: (2018) -
Stabilizing Peri-Stent Restenosis Using a Novel Therapeutic Carrier
por: Kee, Patrick H., et al.
Publicado: (2019) -
Impact of Neointimal Calcifications on Acute Stent Performance during
the Treatment of In-Stent Restenosis
por: Mehanna, Emile, et al.
Publicado: (2016) -
The effect of sex differences on neointimal characteristics of in-stent restenosis in drug-eluting stents: An optical coherence tomography study
por: Yuan, Xiaohang, et al.
Publicado: (2023) -
The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit
por: Di Bartolo, Belinda A, et al.
Publicado: (2011)